Treatment satisfaction, symptom control, and quality of life (QoL) with lanreotide autogel (LAN) in neuroendocrine tumour (NET) patients with carcinoid syndrome (CS): results from the SymNET study

Konference: 2014 39th Congress ESMO - účast ČR

Kategorie: Gastrointestinální nádory

Téma: Postery

Číslo abstraktu: 1134PD

Autoři: Prof. M.D. Philippe B. Ruszniewski; Prof. M.D. Martyn E. Caplin, FRCP; M.D. Juan W. Valle; Catherine Lombard-Bohas; Graeme John Poston; M.D. Petros Perros, BSc, MBBS, FRCP; Doc. MUDr. Luboš Holubec (jr.), Ph.D., MBA; Prof. M.D. Gianfranco Delle Fave; Denis Michel Smith; Patricia Niccoli; Pascal Maisonobe; Philippe Atlan


CS associated with NETs can have a negative impact on patients' QoL. Here, QoL data are evaluated from the SymNET study.



SymNET was a large observational study of NET patients with a history of CS-related diarrhoea treated with LAN for >3 mo (NCT01234168). Patient-reported outcomes were assessed at a routine clinic visit. Primary endpoint was patient satisfaction with diarrhoea control (PSD). Symptoms were evaluated using medical records. QoL was assessed using the EORTC QLQ-C30 and QLQ-GI.NET21 questionnaires, which assess functional dimensions (QLQ-C30; higher scores = better QoL) and symptoms (QLQ-C30 and QLQ-GI.NET21; lower scores = better QoL). Overall QoL was evaluated according to satisfaction with CS symptom control.



Among 273 patients enrolled, 76% [95% CI: 70, 81%] were ‘completely’ or ‘rather’ satisfied with diarrhoea control. There was a clinically significant reduction in stool number and statistically significant improvements in urgency, leakage, and associated pain since LAN initiation. Scores for the QLQ-C30 global health status were high (mean [SD] 65.5 [22.1], median [range] 66.7 [0–100]), while scores for the QLQ-GI.NET21 endocrine and gastrointestinal subscales were low (endocrine, mean [SD] 19.4 [21.3], median [range] 11.1 [0–100]; gastrointestinal, mean [SD] 22.9 [17.8], median [range] 20.0 [0–87]). Patients who expressed a high PSD scored well on their overall rating of QoL (Table); in total, 70% of patients who were ‘rather’ or ‘completely satisfied’ had ‘good’, ‘very good’, or ‘excellent’ QoL.

QoL according to PSD

    n (%)  
  Rather' or ‘completely’ satisfied(n = 200) Neither satisfied nor dissatisfied(n = 46) ‘Rather’ or ‘completely’ dissatisfied(n = 18)
Overall QoL      
Very poor, poor, or slightly poor 28 (14) 12 (26) 5 (28)
Neither poor nor good 32 (16) 12 (26) 6 (33)
Good, very good, or excellent 140 (70) 22 (48) 7 (39)



In a real world setting, CS symptom control with LAN treatment translates into favourable levels of satisfaction among NET patients. Higher satisfaction levels were consistent with higher global health QoL scores. Further analyses are ongoing to evaluate factors associated with better QoL.



P. Ruszniewski: Ipsen: Consultant/advisory role; honoraria; research funding; partner is Ipsen employee. Novartis: honoraria and research funding; M. Caplin: IPSEN: honoraria for consultant/advisory role. NOVARTIS: Consulting fee, Advisory Committees or Review Panels; LEXICON: Consulting fee, Advisory Committees or Review Panel; J.W. Valle: Ipsen: consulting, honoraria; P. Niccoli: Ipsen: consulting and honoraria; P. Maisonobe: Ipsen: Employment and salary; P. Atlan: Ipsen: Employment and salary. All other authors have declared no conflicts of interest.

Plný text abstraktu v časopise Ann Oncol (2014) 25 (suppl 4)


Datum přednesení příspěvku: 29. 9. 2014